Monday, August 29, 2022 Daily Archives

eBook: MSC-Derived Extracellular Vesicles Challenges in Production, Scale-Up, and Characterization

by , , and

The discovery of extracellular vesicles (EVs) as an intercellular communication medium has led to explorations of their therapeutic potential. EVs constitute a heterogeneous mixture of several different vesicle populations that may be similar in size but different in content, or vice versa. The vesicles can contain RNAs and proteins as well as DNAs and lipids as biological cargoes. Those cargoes can exist either intraluminally within EVs or on their surface, adding complexity to analytical considerations. EVs are classified into subpopulations…

August 29, 2022

Sonoma Bio leases T cell facility in Seattle

by

Sonoma Bio has entered into a long-term lease agreement to develop an R&D and manufacturing plant in Seattle, Washington. According to Sonoma Biotherapeutics, the 83,000 square-foot center will be dedicated to research, development, and production of gene-modified regulatory T cell (Treg) therapies for inflammatory and autoimmune diseases at scale for its upcoming clinical trials. “Sonoma Bio is at the forefront of developing Treg therapies to treat autoimmune and inflammatory diseases by restoring balance to the immune system, and we are…

August 29, 2022

Porton Advanced raises $80m for CGT CDMO Operations

by

Chinese cell and gene therapy (CGT) CDMO Porton Advanced Solutions has completed an $80 million Series B round to expand its business into new markets. The Suzhou, China-based company has built an integrated contract development and manufacturing organization (CDMO) platform that provides plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy and microbial vectors used for gene therapy. Currently, Porton has a 40,000 square-foot R&D and GMP production facility that has been operating for over two years. It expects a…

August 29, 2022